Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | PRKCG | P05129 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10273087 | 0.80 | MAPK14 (0.55) | MAPK14MAPK1KDRMAPK9PRKD2 | |
| SCHEMBL765550 | 0.75 | AXL (0.42) | MAPK14MAPK13MAPK12MAPK11PDE4A | |
| SCHEMBL764216 | 0.73 | KCNH2 (0.41) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL752399 | 0.69 | KDM4C (0.39) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL751894 | 0.67 | USP7 (0.38) | MAPK14 | |
| SCHEMBL8860209 | 0.66 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL4543395 | 0.64 | NR3C2 (0.62) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL13376809 | 0.64 | ALDH1A1 (0.43) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL25231757 | 0.63 | BUB1 (0.38) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL15932994 | 0.63 | ALK (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439174-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | MAPK14 2186/4885MAPK13 1997/4885MAPK12 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.